Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Elotuzumab: First Global Approval.

Literature DB >> 26809244

Elotuzumab: First Global Approval.

Abstract

Elotuzumab (Empliciti™) is a humanised IgG1 monoclonal antibody developed by Bristol-Myers Squibb (BMS) and AbbVie that has been approved as combination therapy with lenalidomide and dexamethasone for relapsed/refractory multiple myeloma in the US. Elotuzumab binds to the cell surface receptor signalling lymphocytic activation molecule F7 (SLAMF7), which is selectively expressed on myeloma cells and natural killer cells, leading to antibody-dependent cellular cytotoxicity and direct natural killer cell activation. In a phase III clinical trial, addition of elotuzumab to lenalidomide and dexamethasone therapy in patients with relapsed/refractory multiple myeloma was associated with a significant improvement in progression-free survival and overall response rate. This article summarizes the milestones in the development of elotuzumab leading to this first approval for relapsed/refractory multiple myeloma.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2016 PMID： 26809244 DOI： 10.1007/s40265-016-0540-0

Source DB: PubMed Journal: Drugs ISSN： 0012-6667 Impact factor: 9.546

10 in total

1. Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.

Authors: Paul G Richardson; Sundar Jagannath; Philippe Moreau; Andrzej J Jakubowiak; Marc S Raab; Thierry Facon; Ravi Vij; Darrell White; Donna E Reece; Lotfi Benboubker; Jeffrey Zonder; L Claire Tsao; Kenneth C Anderson; Eric Bleickardt; Anil K Singhal; Sagar Lonial
Journal: Lancet Haematol Date: 2015-11-16 Impact factor: 18.959

2. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.

Authors: Sagar Lonial; Meletios Dimopoulos; Antonio Palumbo; Darrell White; Sebastian Grosicki; Ivan Spicka; Adam Walter-Croneck; Philippe Moreau; Maria-Victoria Mateos; Hila Magen; Andrew Belch; Donna Reece; Meral Beksac; Andrew Spencer; Heather Oakervee; Robert Z Orlowski; Masafumi Taniwaki; Christoph Röllig; Hermann Einsele; Ka Lung Wu; Anil Singhal; Jesus San-Miguel; Morio Matsumoto; Jessica Katz; Eric Bleickardt; Valerie Poulart; Kenneth C Anderson; Paul Richardson
Journal: N Engl J Med Date: 2015-06-02 Impact factor: 91.245

3. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myeloma.

Authors: Andrzej J Jakubowiak; Don M Benson; William Bensinger; David S D Siegel; Todd M Zimmerman; Ann Mohrbacher; Paul G Richardson; Daniel E H Afar; Anil K Singhal; Kenneth C Anderson
Journal: J Clin Oncol Date: 2012-01-30 Impact factor: 44.544

4. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma.

Authors: Eric D Hsi; Roxanne Steinle; Balaji Balasa; Susann Szmania; Aparna Draksharapu; Benny P Shum; Mahrukh Huseni; David Powers; Amulya Nanisetti; Yin Zhang; Audie G Rice; Anne van Abbema; Melanie Wong; Gao Liu; Fenghuang Zhan; Myles Dillon; Shihao Chen; Susan Rhodes; Franklin Fuh; Naoya Tsurushita; Shankar Kumar; Vladimir Vexler; John D Shaughnessy; Bart Barlogie; Frits van Rhee; Mohamad Hussein; Daniel E H Afar; Marna B Williams
Journal: Clin Cancer Res Date: 2008-05-01 Impact factor: 12.531

5. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu.

Authors: Yu-Tzu Tai; Myles Dillon; Weihua Song; Merav Leiba; Xian-Feng Li; Peter Burger; Alfred I Lee; Klaus Podar; Teru Hideshima; Audie G Rice; Anne van Abbema; Lynne Jesaitis; Ingrid Caras; Debbie Law; Edie Weller; Wanling Xie; Paul Richardson; Nikhil C Munshi; Claire Mathiot; Hervé Avet-Loiseau; Daniel E H Afar; Kenneth C Anderson
Journal: Blood Date: 2007-09-28 Impact factor: 22.113

6. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC.

Authors: Shauna M Collins; Courtney E Bakan; Gina D Swartzel; Craig C Hofmeister; Yvonne A Efebera; Hakju Kwon; Gary C Starling; David Ciarlariello; Shakthi Bhaskar; Edward L Briercheck; Tiffany Hughes; Jianhua Yu; Audie Rice; Don M Benson
Journal: Cancer Immunol Immunother Date: 2013-10-26 Impact factor: 6.968

7. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.

Authors: Frits van Rhee; Susann M Szmania; Myles Dillon; Anne M van Abbema; Xin Li; Mary K Stone; Tarun K Garg; JuMei Shi; Amberly M Moreno-Bost; Rui Yun; Balaji Balasa; Bishwa Ganguly; Debra Chao; Audie G Rice; Fenghuang Zhan; John D Shaughnessy; Bart Barlogie; Shmuel Yaccoby; Daniel E H Afar
Journal: Mol Cancer Ther Date: 2009-09-01 Impact factor: 6.261

8. Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211.

Authors: S Z Usmani; R Sexton; S Ailawadhi; J J Shah; J Valent; M Rosenzweig; B Lipe; J A Zonder; S Fredette; B Durie; A Hoering; B Bartlett; R Z Orlowski
Journal: Blood Cancer J Date: 2015-08-07 Impact factor: 11.037

Review 9. Mechanisms of Drug Resistance in Relapse and Refractory Multiple Myeloma.

Authors: Wen-Chi Yang; Sheng-Fung Lin
Journal: Biomed Res Int Date: 2015-11-16 Impact factor: 3.411

10. Pharmacokinetics and Safety of Elotuzumab Combined With Lenalidomide and Dexamethasone in Patients With Multiple Myeloma and Various Levels of Renal Impairment: Results of a Phase Ib Study.

Authors: Jesus Berdeja; Sundar Jagannath; Jeffrey Zonder; Ashraf Badros; Jonathan L Kaufman; Robert Manges; Manish Gupta; Amol Tendolkar; Mark Lynch; Eric Bleickardt; Prashni Paliwal; Ravi Vij
Journal: Clin Lymphoma Myeloma Leuk Date: 2015-12-21

10 in total

6 in total

Review 1. Polysaccharide-based nanomedicines for cancer immunotherapy: A review.

Authors: Yujun Zeng; Yufan Xiang; Ruilong Sheng; Helena Tomás; João Rodrigues; Zhongwei Gu; Hu Zhang; Qiyong Gong; Kui Luo
Journal: Bioact Mater Date: 2021-03-18

Review 2. Elotuzumab: The First Monoclonal Antibody for the Treatment of Multiple Myeloma.

Authors: Karen M Fancher; Elizabeth J Bunk
Journal: J Adv Pract Oncol Date: 2016-07-01

3. IL21R expressing CD14⁺CD16⁺ monocytes expand in multiple myeloma patients leading to increased osteoclasts.

Authors: Marina Bolzoni; Domenica Ronchetti; Paola Storti; Gaetano Donofrio; Valentina Marchica; Federica Costa; Luca Agnelli; Denise Toscani; Rosanna Vescovini; Katia Todoerti; Sabrina Bonomini; Gabriella Sammarelli; Andrea Vecchi; Daniela Guasco; Fabrizio Accardi; Benedetta Dalla Palma; Barbara Gamberi; Carlo Ferrari; Antonino Neri; Franco Aversa; Nicola Giuliani
Journal: Haematologica Date: 2017-01-05 Impact factor: 9.941